Abstract
A recent study of multidrug resistance (MDR) 1 gene transfected osteosarcoma cells found a cause-effect relationship between increased expression of P-glycoprotein (P-gp) and a low aggressive phenotype. However, several experimental and clinical studies have observed contradictory findings in that P-gp expression has been associated with tumour progression. In the present study, we characterized P-gp-positive and P-gp-negative single-cell clones of a murine osteosarcoma, to further investigate the relationship between P-gp expression and changes in cell phenotype. Although these clones were all selected by doxorubicin (DOX) exposure, they were heterogeneous with respect to MDR1 gene expression. The P-gp-positive clones revealed MDR phenotype, whereas the P-gp-negative clones showed no resistance to drugs. Morphological and functional analysis showed that both the P-gp-positive and P-gp-negative clones were more differentiated than the parent cells in terms of enhanced activity of cellular alkaline phosphatase, an increase in well-organized actin stress fibres and enhanced osteogenic activity. Moreover, these subclones all displayed a decrease in malignant potential such as oncogenic activity, tumour growth rate and metastatic ability, regardless of their P-gp status. These results indicate that the observed osteoblastic differentiation and less aggressive phenotype in DOX-selected osteosarcoma cells may not only be explained by the direct effect of P-gp, and accordingly, consideration of the effect of DOX, as well as P-gp, appears to be important. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M and Serra M (1995) P-glycoprotein expression and outcome in high grade osteosarcoma. N Engl J Med 333: 1380–1385
Biedler JL (1994) Drug resistance: genotype versus phenotype. Thirty-second GHA Clowes Memorial Award Lecture. Cancer Res 54: 666–678
Biedler JL and Spengler BA (1994) Reverse transformation of multidrug-resistant cells. Cancer Metastasis Rev 13: 191–207
Bosch I and Croop J (1996) P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1288: F37–F54
Bradley G and Ling V (1994) P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 13: 223–233
Bradley G, Sharma R, Rajalakshmi S and Ling V (1992) P-glycoprotein expression during tumor progression in the rat liver. Cancer Res 52: 5154–5161
Chan HSL, Haddad G, Thorner PS, DeBoer G, Lin UP, Ondrusek N, Yeger H and Ling V (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608–1614
Fairchild CG, Ivy SP, Rushmore T, Lee G, Koo P, Goldsmith ME, Myers CE, Farber E and Cowan KH (1987) Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci USA 84: 7710–7705
Fardel O, Lecureur V, Daval S, Corlu A and Guillouzo A (1997) Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 246: 186–192
Hansen MB, Nielsen SE and Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203–210
Hirsch-Ernst KI, Ziemann C, Schmitz-Salue C, Foth H and Kahl GF (1995) Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Biochem Biophys Res Commun 215: 179–185
Hirsch-Ernst KI, Ziemann C, Foth H, Kozian D, Schmitz-Salue C and Kahl GF (1998) Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. J Cell Physiol 176: 506–515
Jaffe N (1993) Osteosarcoma: contribution of chemotherapy to treatment of the primary tumor. In: Frontiers of Osteosarcoma Research: Interdisciplinary Survey of Clinical and Research Advances, Novak JF, Mcmaster JH (eds), pp. 25–40. Hogrefe & Huber: Kirkland
Link MP (1993) Preoperative and adjuvant chemotherapy in osteosarcoma. In: Frontiers of Osteosarcoma Research: Interdisciplinary Survey of Clinical and Research Advances, Novak JF, Mcmaster JH (eds), pp. 41–49 Hogrefe & Huber: Kirkland
Lowly OH (1955) Micromethods for the assay of enzyme II. Specific procedures. Alkaline phosphatase. Meth Enzymol 4: 371–372
Mickerley LA, Bates ASE, Richert ND, Currier S, Tanaka S, Foss F, Rosen N and Fojo AT (1989) Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biol Chem 264: 18031–18040
Morceau F, Chenais B, Gillet R, Jardillier JC, Jeannesson P and Trentesaux C (1996) Transcriptional and post-transcriptional regulation of erythroid gene expression in anthracyclin-induced differentiation of human erythroleukemic cells. Cell Growth Differ 7: 1023–1029
Scotlandi K, Serra MC, Nicoletti G, Vaccari M, Manara MC, Nini G, Landuzzi L, Colacci A, Bacci G, Bertoni F, Picci P, Campanacci M and Baldini N (1996) Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 56: 2434–2439
Scotlandi K, Manara MC, Serra M, Benini S, Maurici D, Caputo A, Giobanni CD, Lollini P-L, Nanni P, Picci P, Campanacci M and Baldini N (1999) The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcomas. Oncogene 18: 739–746
Serra M, Scotlandi K, Manara MC, Maurici D, Benini S, Sarti M, Campanacci M and Baldini N (1995) Analysis of P-glycoprotein expression in osteosarcoma. Eur J Cancer 31A: 1998–2002
Takeshita H, Gebhardt MC, Springfield DS, Kusuzaki K and Mankin HJ (1996) Experimental models for the study of drug resistance in osteosarcoma; P-glycoprotein-positive murine osteosarcoma cell lines. J Bone Joint Surg 78-A: 366–375
Takeshita H, Kusuzaki K, Tsuji Y, Hirata M, Hashiguchi S, Nakamura S, Murata H, Ashihara T and Hirasawa Y (1998) Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209. Anticancer Res 18: 739–742
Uchiumi T, Kohno K, Tanimura H, Matsuo K, Sato S, Uchida Y and Kuwano M (1993) Enhanced expression of the human multidrug resistance 1 gene response to UV light irradiation. Cell Growth Differ 4: 147–157
Weinstein RS, Jakate SM, Dominguez JM, Lebovits MD, Koukoulis GK, Kuszak JR, Grogan TM, Saclarides TJ, Roninson IB and Coon JS (1991) Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720–2726
Wulf E, Deboben A, Bautz FA, Faulstich H and Wieland TH (1979) Fluorescent phallotoxin, a tool for the visualization of cellular actin. Proc Natl Acad Sci USA 76: 4498–4502
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Takeshita, H., Kusuzaki, K., Murata, H. et al. Osteoblastic differentiation and P-glycoprotein multidrug resistance in a murine osteosarcoma model. Br J Cancer 82, 1327–1331 (2000). https://doi.org/10.1054/bjoc.1999.1099
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1099